Table 2.
Competitive environment.
| Agent | Indication | Development stage | Mechanism of action |
|---|---|---|---|
| Brentuximab vedotin | HL, NHL | Approved for HL and NHL | Anti-CD30 antibody-drug conjugate |
|
| |||
| Bendamustine | NHL, MM | Approved for NHL | Bifunctional alkylating agent |
|
| |||
| Panobinostat | AML, CML, breast cancer, prostate cancer, MM, idiopathic myelofibrosis, HL, NHL | Approved for MM | HDAC inhibitor |
|
| |||
| Mocetinostat | AML, solid tumors, CLL, MDS, NHL, HL | Phase II | HDAC inhibitor |
|
| |||
| Everolimus | Solid tumors, transplant rejection, HL, NHL | Approved for solid tumors and transplant rejection | mTOR inhibitor |
|
| |||
| Pacritinib | AML, myeloproliferative disorders, HL, NHL | Phase III | JAK2-inhibitor |
|
| |||
| Rituximab | NHL, CLL, rheumatoid arthritis, HL, granulomatosis, multiple sclerosis, MM | Approved for NHL, rheumatoid arthritis, granulomatosis, CLL | Anti-CD20 antibody |
|
| |||
| Lenalidomide | MDS, MM, NHL, HL, CLL | Approved for MDS, MM | Immunomodulator |
|
| |||
| Nivolumab | Melanoma, lung cancer, renal cancer, HL | Phase I | Anti-PD1 antibody |
|
| |||
| Pembrolizumab | Melanoma, lung cancer, renal cancer, HL | Phase I | Anti-PD1 antibody |
HL: Hodgkin lymphoma; NHL: non-Hodgkin lymphoma; MM: multiple myeloma; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; CLL: chronic lymphatic leukemia.